**Core tip:** Ten induced pluripotent stem cell (iPSC) lines were clonally generated from heterogeneous colon cancer tissues and analyzed with next-generation sequencing. Non-synonymous single-nucleotide variants (SNVs) of the iPSC lines were not identical to the genotypes of the cancer tissues. The SNVs were *de novo* or pre-existing mutations that originated from a minor population within the cancer tissue. Meanwhile, the genotypes of the iPSC lines were not mutated genotypes of the cancer tissues, suggesting that the starting cells for the iPSC lines were not mature cancer cells. Thus, the genotypes of iPSC lines can be used to trace the genomic origins of single cells within heterogeneous cancer tissue.

INTRODUCTION
============

Gene transfer of *OCT3/4, SOX2*, *KLF4*, and *c-Myc* to somatic cells generates human induced pluripotent stem cells (iPSCs)\[[@B1]-[@B3]\] although *c-MYC* is not required for iPSC generation\[[@B4]\]. Human iPSCs are indistinguishable from human embryonic stem cells (ESCs) in terms of their long-term self-renewal ability and their *in vivo* pluripotency\[[@B3],[@B5]\]. The starting cells for iPSC generation should be appropriately chosen to generate normal or aberrant iPSC lines for the purpose of regenerative medicine or cancer research/therapy. Human iPSC lines for regenerative medicine would be ideally generated from normal neonatal tissues\[[@B3]\] that are typically free of postnatal aberrant mutations and epigenetic changes. Human iPSCs (or iPSC-like cells) have also been generated from cancer cell lines\[[@B6],[@B7]\], the somatic cells from familial cancer patients\[[@B8],[@B9]\], and pancreatic ductal adenocarcinomas\[[@B10]\]. For cancer research/therapy, it is of great interest to generate iPSCs from heterogeneous cancer tissues. In our recent study\[[@B11]\], human iPSC lines were clonally generated from a heterogeneous mixture of primary cells derived from gastric tissues or colon cancer tissues and were subjected to microarray gene expression analysis. The resultant iPSC lines expressed all ESC-enriched genes including *POU5F1, SOX2* and *NANOG* that are essential for self-renewal ability and pluripotency\[[@B5],[@B12]\] at a level equivalent to those of the typical human iPSC line (201B7)\[[@B1]\]. Genome-wide gene expression patterns were used to categorize the reference iPSC line 201B7 and the iPSC lines derived from distinct cancer tissues into three different groups. The gene expression profiles of these iPSC lines demonstrated differences derived from their distinct starting tissues and similarity and heterogeneity derived from their common starting heterogeneous tissues. More recently, it was reported that reference component analysis (RCA), an algorithm that substantially improves clustering accuracy, was developed to robustly cluster single-cell transcriptomes\[[@B13]\]. The RCA of single-cell transcriptomes elucidated cellular heterogeneity in human colorectal cancer\[[@B13]\].

In this study, iPSC technology and next-generation sequencing were used to resolve genotype variation among single cells within a heterogeneous cancer tissue. The genomic DNA of ten iPSC lines that were clonally generated from human colon cancer tissue was analyzed and compared with the genomic DNA from their cancer tissue of origin and matched adjacent non-cancerous tissue.

MATERIALS AND METHODS
=====================

Tissues derived from a single colon cancer patient
--------------------------------------------------

This study was conducted with the approval of the Institutional Review Boards of the National Cancer Center of Japan and the Japanese Collection of Research Bioresources (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition. Written informed consent from a single donor was obtained for the use of the tissues for research. The anonymous remnant non-cancerous and cancerous tissues were provided by the JCRB Tissue Bank. The tissues were derived from the surgical waste material from an operation performed on a 55-year-old Japanese male S-shaped colon cancer patient.

Primary cell culture from cancer tissues
----------------------------------------

Heterogeneous primary cell culture from the colon cancer tissues was prepared as previously described\[[@B11]\]. Briefly, the tissues were washed with Hank's balanced salt solution (HBSS) and minced into pieces with scissors. The pieces were further washed with HBSS. DMEM with collagenase was added to the tissue precipitates and mixed at 37 °C for 1 h on a shaker. After washing with DMEM, cells were seeded on collagen-coated dishes and cultured in DMEM supplemented with 10% FBS.

Generation of human iPSC lines
------------------------------

The study was approved by the Institutional Recombinant DNA Advisory Committee. Heterogeneous primary cells from the cancer tissue were cultured for 24 h at approximately 5%-10% confluency and then incubated with a pantropic retrovirus vector solution (*OCT3/4*, *KLF4*, and *SOX2*) at 37 °C for an additional 24 h. The vector solution was prepared as previously described\[[@B14]\]. Mitomycin C-treated mouse embryonic fibroblasts (MEFs, ReproCell) were seeded and co-cultured with the primary cells following the retroviral infection. The culture medium was replaced with MEF-conditioned ESC medium every 3 d until the cell layer was fully confluent and then further refreshed with mTeSR1 medium (STEMCELL Technologies) every day. Each independent colony was isolated from the culture using forceps under a microscope. The independent iPSC lines were sub-cultured with MEF in gelatin-coated 24-well plates.

Expansion and passage culture of human iPSC lines
-------------------------------------------------

Human iPSC lines were cultured with the MEFs in primate ESC, ReproStem (ReproCell) or mTeSR1 medium in gelatin-coated dishes\[[@B11]\]. The expanded iPSC lines were treated with a dissociation solution (ReproCell) or 0.25% trypsin-EDTA (Gibco) and passaged in media supplemented with 10-20 μmol/L Y-27632 to avoid cell death\[[@B3]\]. Independent iPSC lines were passaged from the 24-well plates into 6-well plates, further expanded into 100-mm dishes, and minimally passaged in 100-mm dishes under similar culture conditions. Each genomic DNA sample was prepared from independent iPSC lines.

Real-time RT-PCR analysis
-------------------------

Total RNA was prepared using the miRNeasy Mini Kit (Qiagen). Reverse transcription of the RNA was carried out using an iScript™ Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad). Quantitative PCR was carried out with an SsoAdvanced Universal SYBR^®^ Green Supermix using the CFX96 Real-Time PCR Detection System (Bio-Rad). PCR primer sets for *OCT3/4*, *SOX2*, *NANOG*, *ZFP42*, and *GAPDH* are listed in Supplemental Table 1. PCR data were analyzed using CFX Manager Software (Bio-Rad). PCR data from the iPSC 201B7\[[@B1]\] RNA were used as a positive control, and PCR data from cancer tissue-derived iPSC lines are presented as quantification cycle (Cq) values.

###### 

Read number (original)

             **Original**         
  ---------- -------------- ----- -----
  NCC1       18260718       101   3.7
  18260718   101                  
  CC1        16706190       101   3.4
  16706190   101                  
  CC1-1      13045740       101   2.6
  13045740   101                  
  CC1-2      17725772       101   3.6
  17725772   101                  
  CC1-7      14780507       101   3.0
  14780507   101                  
  CC1-8      17311972       101   3.5
  17311972   101                  
  CC1-9      16664067       101   3.4
  16664067   101                  
  CC1-11     15455638       101   3.1
  15455638   101                  
  CC1-12     15391361       101   3.1
  15391361   101                  
  CC1-17     19009957       101   3.8
  19009957   101                  
  CC1-18     19746313       101   4.0
  19746313   101                  
  CC1-25     15492560       101   3.1
  15492560   101                  

NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the induced pluripotent stem cell lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line.

Target selection and sequencing
-------------------------------

Target sequencing was conducted for twelve DNA samples from the cancer tissues, the non-cancerous tissues, and the ten iPSC lines. Genomic DNA was extracted from each of twelve samples using the DNeasy Blood AND Tissue Kit (Qiagen), sheared into approximately 150-bp fragments, and used to make a library for multiplexed paired-end sequencing with the SureSelect^XT^ Reagent Kit (Agilent Technologies). The constructed library was hybridized to biotinylated cRNA oligonucleotide baits from the SureSelect^XT^ Human Kinome Kit (Agilent Technologies) for target enrichment. Targeted sequences were purified by magnetic beads, amplified, and sequenced on an Illumina HiSeq2000 platform in a paired-end 101 bp configuration.

Mapping and single-nucleotide variant calling
---------------------------------------------

Adapter sequences were removed by cutadapt (v1.2.1). After quality control, reads were mapped to the human reference genome hg19 using BWA (ver.0.6.2). Mapping results were corrected using Picard (ver.1.73) for removing duplicates and GATK (ver.1.5-32) for local alignment and base quality score recalibration. Single-nucleotide variant (SNV) calls were performed with multi-sample calling using GATK (UnifiedGenotyper) and filtered to coordinates with a variant call quality score ≥ 30 and a depth ≥ 8. SNVs were further classified based on their predicted functions of missense, nonsense or read-through. For final confirmation, SNVs were manually curated using the Integrative Genomics Viewer. Annotations of SNVs were based on dbSNP135, CCDS (NCBI release 20111122), RefSeq (UCSC Genome Browser, dumped 20111122), GENCODE (UCSC Genome Browser, ver. 7), and 1000 Genomes (release 20111011) sequences.

RESULTS
=======

Human iPSC lines derived from colon cancer tissues
--------------------------------------------------

The human iPSC lines CC1-1, CC1-2, CC1-7, CC1-8, CC1-9, CC1-11, CC1-12, CC1-17, CC1-18, and CC1-25 were clonally generated from heterogeneous primary cells cultured from colon cancer tissue. The iPSC lines were expanded serially with MEFs in gelatin-coated dishes. The cancer tissue-derived iPSCs were indistinguishable in morphology from typical (fibroblast-derived) human iPSCs under conventional culture with MEFs (upper panels in Figure [1](#F1){ref-type="fig"} and Supplemental Figure 1). The human iPSCs formed colonies consisting of very small cells and were efficiently passaged at a high recovery ratio with the addition of 10-20 μmol/L Y-27632 to the cell culture medium. Human iPSCs were also cultured with feeder-free mTeSR1 medium in BD Matrigel^TM^-coated 100-mm dishes and showed a high nucleus-to-cytoplasm ratio (lower panels in Figure [1](#F1){ref-type="fig"} and Supplemental Figure 1).

![Phase contrast micrographs of colon cancer tissue-derived induced pluripotent stem cells. The human iPSC line CC1-1 was expanded with mitomycin C-treated mouse embryonic fibroblasts in gelatin-coated dishes (upper left panel: × 10, upper right panel: × 20) and cultured with feeder-free mTeSR1 medium in BD Matrigel^TM^-coated dishes (lower left panel: × 10, lower right panel: × 20). iPSC: Induced pluripotent stem cell; MEF: Mouse embryonic fibroblast.](WJSC-9-77-g001){#F1}

Expression of human ESC-essential genes
---------------------------------------

ESC-essential gene expression of the cancer tissue-derived iPSC lines was quantitatively analyzed by real-time RT-PCR. All ten iPSC lines expressed *POU5F1, SOX2*, and *NANOG*, which are essential for self-renewal and pluripotency, at a level equivalent to those of the reference iPSC line (Supplemental Table 2). The study results support previously published microarray data showing that cancer tissue-derived iPSCs equally express ESC-enriched genes\[[@B11]\].

###### 

Read number (modified)

             **Modified[1](#T2FN1){ref-type="table-fn"}**                                         
  ---------- ---------------------------------------------- ------------------------------------- -------
  NCC1       18146940                                       101[2](#T2FN2){ref-type="table-fn"}   99.38
  18146940   101[2](#T2FN2){ref-type="table-fn"}            99.38                                 
  CC1        16597436                                       101[2](#T2FN2){ref-type="table-fn"}   99.35
  16597436   101[2](#T2FN2){ref-type="table-fn"}            99.35                                 
  CC1-1      12942132                                       101[2](#T2FN2){ref-type="table-fn"}   99.21
  12942132   101[2](#T2FN2){ref-type="table-fn"}            99.21                                 
  CC1-2      17614866                                       101[2](#T2FN2){ref-type="table-fn"}   99.37
  17614866   101[2](#T2FN2){ref-type="table-fn"}            99.37                                 
  CC1-7      14687008                                       101[2](#T2FN2){ref-type="table-fn"}   99.37
  14687008   101[2](#T2FN2){ref-type="table-fn"}            99.37                                 
  CC1-8      17180329                                       101[2](#T2FN2){ref-type="table-fn"}   99.24
  17180329   101[2](#T2FN2){ref-type="table-fn"}            99.24                                 
  CC1-9      16545785                                       101[2](#T2FN2){ref-type="table-fn"}   99.29
  16545785   101[2](#T2FN2){ref-type="table-fn"}            99.29                                 
  CC1-11     15346749                                       101[2](#T2FN2){ref-type="table-fn"}   99.30
  15346749   101[2](#T2FN2){ref-type="table-fn"}            99.30                                 
  CC1-12     15281269                                       101[2](#T2FN2){ref-type="table-fn"}   99.28
  15281269   101[2](#T2FN2){ref-type="table-fn"}            99.28                                 
  CC1-17     18880292                                       101[2](#T2FN2){ref-type="table-fn"}   99.32
  18880292   101[2](#T2FN2){ref-type="table-fn"}            99.32                                 
  CC1-18     19618808                                       101[2](#T2FN2){ref-type="table-fn"}   99.35
  19618808   101[2](#T2FN2){ref-type="table-fn"}            99.35                                 
  CC1-25     15378555                                       101[2](#T2FN2){ref-type="table-fn"}   99.26
  15378555   101[2](#T2FN2){ref-type="table-fn"}            99.26                                 

Modified read file is a data set from the original read file with the adapter sequences and low-quality bases removed;

Therefore, there were reads shorter than the number indicated by the read length (b) in a portion of the modified read file. NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the induced pluripotent stem cell lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line.

Next-generation sequencing
--------------------------

The target region (SureSelect Human Kinome) in genomic DNA samples from the ten iPSC lines, their starting cancer tissues, and the matched adjacent non-cancerous tissues was analyzed using next-generation sequencing. The target region of approximately 3.2 Mb covers the genome of the coding region of all known protein kinase genes and selected oncogenes and tumor suppressor genes, for a total of 612 genes (Supplemental Table 3). The original reads (2.6-4.0 Gb of sequence) were obtained from each genomic DNA sample by sequencing (Table [1](#T1){ref-type="table"}). The modified reads were generated from the original reads (Table [2](#T2){ref-type="table"}). The results of the mapped reads, the sequencing depth, and target capture are summarized in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. The average depth on the target region ranged from 317 to 496. More than 99.76% of the target region was covered with at least 8 × depth for high-quality genotype calls (variant call quality score ≥ 30).

###### 

Mapped reads

                                                             **NCC1**   **CC1**    **CC1-1**   **CC1-2**   **CC1-7**   **CC1-8**   **CC1-9**   **CC1-11**   **CC1-12**   **CC1-17**   **CC1-18**   **CC1-25**
  ---------------------------------------------------------- ---------- ---------- ----------- ----------- ----------- ----------- ----------- ------------ ------------ ------------ ------------ ------------
  No. of total reads ①                                       36293880   33194872   25884264    35229732    29374016    34360658    33091570    30693498     30562538     37760584     39237616     30757110
  No. of mapped reads ② (③+ ④ + ⑤)                           36210841   33066194   25545096    34845596    28911555    33842665    32976780    29898986     30464308     36670526     38078508     30173511
  No. of mapped reads with Paired-End ③                      26935180   26333748   21884450    25981140    21498822    26807330    26704280    25386830     25103580     29513694     30869186     21622036
  No. of mapped reads with Single-End ④                      15741      24050      14051       16508       12336       17984       14651       27429        14354        27336        25456        19687
  No. of discarded reads[1](#T3FN1){ref-type="table-fn"} ⑤   9259920    6708396    3646595     8847948     7400397     7017351     6257849     4484727      5346374      7129496      7183866      8531788
  No. of unmapped reads (①‐②)                                83039      128678     339168      384136      462461      517993      114790      794512       98230        1090058      1159108      583599
  No. of effective reads (③ + ④)                             26950921   26357798   21898501    25997648    21511158    26825314    26718931    25414259     25117934     29541030     30894642     21641723

Discarded reads were as follows: Reads mapped to chromosomes other than the target; Reads where each paired-end is mapped to a different chromosome; Reads not used for single-nucleotide variant/InDel detection such as PCR duplicates. Each number of ② consists of each total number of \"③ plus ④ plus ⑤\"; \"① - ②\" means \"each number of ① minus each number of ②\"; \"③ + ④\" means \"each number of ③ plus each number of ④\". NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the iPSC lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line.

###### 

Sequence depth

           **Theoretical depth[1](#T4FN1){ref-type="table-fn"}**   **Observed depth[2](#T4FN2){ref-type="table-fn"}**          
  -------- ------------------------------------------------------- ---------------------------------------------------- ------ --------
  NCC1     3689                                                    1173.31                                              1399   445.06
  CC1      3375                                                    1073.43                                              1084   344.89
  CC1-1    2635                                                    838.23                                               999    317.89
  CC1-2    3581                                                    1138.94                                              1279   406.72
  CC1-7    2986                                                    949.69                                               1195   380.13
  CC1-8    3497                                                    1112.35                                              1352   430.01
  CC1-9    3366                                                    1070.72                                              1355   431.06
  CC1-11   3122                                                    993.07                                               1077   342.50
  CC1-12   3109                                                    988.94                                               1359   432.12
  CC1-17   3840                                                    1221.45                                              1407   447.66
  CC1-18   3989                                                    1268.76                                              1559   495.99
  CC1-25   3129                                                    995.45                                               1083   344.37

Theoretical depth calculated from the total number of bases obtained by DNA sequencing;

Observed depth used for single-nucleotide variant/InDel identification;

Theoretical depth \[Total Bases (Mb)\]/\[Target region (Mb)\]. Target region: SureSelect Human Kinome Kit (approximately 3.1 Mb). NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the induced pluripotent stem cell lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line.

###### 

Target capture

                                                               **NCC1**   **CC1**    **CC1-1**   **CC1-2**   **CC1-7**   **CC1-8**   **CC1-9**   **CC1-11**   **CC1-12**   **CC1-17**   **CC1-18**   **CC1-25**
  ------------------------------------------------------------ ---------- ---------- ----------- ----------- ----------- ----------- ----------- ------------ ------------ ------------ ------------ ------------
  Initial bases on target ①                                    3143812    3143812    3143812     3143812     3143812     3143812     3143812     3143812      3143812      3143812      3143812      3143812
  Initial bases near target ②                                  3790645    3790645    3790645     3790645     3790645     3790645     3790645     3790645      3790645      3790645      3790645      3790645
  Initial bases on or near target ③                            6934457    6934457    6934457     6934457     6934457     6934457     6934457     6934457      6934457      6934457      6934457      6934457
  Total effective reads ④                                      26950921   26357798   21898501    25997648    21511158    26825314    26718931    25414259     25117934     29541030     30894642     21641723
  Total effective bases (Mb) ⑤                                 2663       2602       2157        2573        2125        2643        2637        2503         2480         2914         3047         2133
  Read length mean (b)                                         98.91      98.83      98.58       99.02       98.84       98.61       98.77       98.58        98.79        98.74        98.69        98.65
  Read length median (b)                                       101        101        101         101         101         101         101         101          101          101          101          101
  Effective bases on target (Mb) ⑥                             1399       1084       999         1279        1195        1352        1355        1077         1359         1407         1559         1083
  Effective bases near target (Mb) ⑦                           440        342        355         405         380         438         448         327          445          430          450          342
  Effective bases on or near target (Mb) ⑧                     1839       1426       1354        1683        1575        1790        1804        1403         1804         1837         2009         1425
  Fraction of effective bases on target (%) (⑥/⑤)              52.54      41.67      46.32       49.70       56.25       51.14       51.38       43.01        54.78        48.30        51.18        50.75
  Fraction of effective bases near target (%) (⑦/⑤)            16.52      13.14      16.45       15.73       17.88       16.56       17.00       13.05        17.96        14.75        14.77        16.05
  Fraction of effective bases on or near target (%) (⑧/⑤)      69.06      54.82      62.78       65.43       74.12       67.70       68.38       56.06        72.74        63.05        65.95        66.80
  Average sequencing depth on target (⑥/①)                     445.06     344.89     317.89      406.72      380.13      430.01      431.06      342.50       432.12       447.66       495.99       344.37
  Average sequencing depth near target (⑦/②)                   116.05     90.22      93.63       106.76      100.21      115.48      118.31      86.16        117.51       113.43       118.68       90.33
  Average sequencing depth on or near target (⑧/③)             265.21     205.68     195.30      242.75      227.11      258.07      260.10      202.38       260.14       264.96       289.74       205.50
  Base covered on target ⑨                                     3143221    3143152    3142784     3143540     3143280     3143263     3143277     3142887      3143338      3143035      3143296      3142818
  Coverage of target region (%) (⑨/①)                          99.98      99.98      99.97       99.99       99.98       99.98       99.98       99.97        99.98        99.98        99.98        99.97
  Base covered near target ⑩                                   3775671    3773869    3774076     3771915     3768892     3773823     3776942     3760218      3776060      3766215      3762031      3762823
  Coverage of near target region (%) (⑩/②)                     99.60      99.56      99.56       99.51       99.43       99.56       99.64       99.20        99.62        99.36        99.25        99.27
  Fraction of target covered with at least 15 × (%)            99.72      99.62      99.59       99.69       99.65       99.68       99.70       99.55        99.69        99.60        99.68        99.58
  Fraction of target covered with at least 8 × (%)             99.86      99.78      99.78       99.83       99.81       99.82       99.83       99.76        99.83        99.78        99.83        99.77
  Fraction of target covered with at least 4 × (%)             99.93      99.89      99.89       99.90       99.90       99.90       99.91       99.87        99.92        99.89        99.91        99.89
  Fraction of flanking region covered with at least 15 × (%)   86.88      84.24      87.52       85.84       84.62       87.92       89.85       79.85        90.17        84.50        80.72        82.36
  Fraction of flanking region covered with at least 8 × (%)    94.32      93.13      94.66       93.66       92.95       94.70       95.77       89.93        95.87        92.55        89.96        91.39
  Fraction of flanking region covered with at least 4 × (%)    97.85      97.33      97.91       97.50       97.15       97.87       98.27       95.76        98.32        96.86        95.71        96.37

The target region, as covered by the SureSelect Human Kinome Kit, was approx. 3.1 Mb. Near target region was 200 bases forward and backward of the target region. \"⑥/⑤\" means \"each number of ⑥ devided by each number of ⑤\"; \"⑦/⑤\" means \"each number of ⑦ devided by each number of ⑤\"; \"⑧/⑤\" means \"each number of ⑧ devided by each number of ⑤\"; \"⑥/①\" means \"each number of ⑥ devided by each number of ①\"; \"⑦/②\" means \"each number of ⑦ devided by each number of ②\"; \"⑧/③\" means \"each number of ⑧ devided by each number of ③\"; \"⑨/①\" means \"each number of ⑨ devided by each number of ①\"; \"⑩/②\" means \"each number of ⑩ devided by each number of ②\". NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the induced pluripotent stem cell lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line.

Non-synonymous SNVs compared with hg19
--------------------------------------

After sequencing, the reads underwent bioinformatics analysis (Figure [2](#F2){ref-type="fig"}). Through comparison with the human reference genome hg19, the non-synonymous SNVs (missense, nonsense or read-through) were called on the target region (on and near DNA target enrichment baits) of twelve samples (the ten iPSC lines, their starting cancer tissues, and the matched adjacent non-cancerous tissues). Of the resulting 378 non-synonymous SNVs (Supplemental Table 4), 50 were novel SNVs (not reported in dbSNP135 or 1000 Genomes, Supplemental Table 5).

![Pipeline of bioinformatics analysis following next-generation sequencing. The thirteen confirmed SNVs are shown in Tables [6](#T6){ref-type="table"}-[8](#T8){ref-type="table"}. SNVs: Single-nucleotide variants.](WJSC-9-77-g002){#F2}

Confirmed genotypes of the twelve samples
-----------------------------------------

Of the 378 non-synonymous SNVs from the twelve samples, 40 were distinct heteroallelic genotypes and included known SNVs in the 612 sequenced gene target region. Supplemental Table 6 lists the forty SNVs that were distinct among the human iPSC lines, their starting cancer tissue, and the matched adjacent non-cancerous tissues. The allelic depth and genotype quality of thirteen of the forty SNVs were validated and manually curated using the Integrative Genomics Viewer (Figure [2](#F2){ref-type="fig"}).

Mutated genotypes of cancer tissue-derived iPSC lines
-----------------------------------------------------

The chromosome number, genome position, novelty, gene symbol, and mutation type of the thirteen confirmed SNVs are shown in Table [6](#T6){ref-type="table"}; the allelic depth is shown in Table [7](#T7){ref-type="table"}; and the genotype is shown in Table [8](#T8){ref-type="table"}. The respective SNVs of the ten iPSC lines were compared to those of their starting cancer tissue and the matched non-cancerous tissue. The genotypes, which showed nonsense or missense mutations in *EIF2AK2, TTN, ULK4, TSSK1B, FLT4, STK19, STK31, TRRAP, WNK1, PLK1*, or *PIK3*R5 (Table [6](#T6){ref-type="table"}), of the iPSC lines were different from that of the non-cancerous tissue sample (Table [8](#T8){ref-type="table"}). Nevertheless, the genotypes of the iPSC samples were also different from that of the starting cancer tissue sample. The heteroallelic read sequences of *ULK4, TRRAP*, and *WNK1* of the starting cancer tissue sample consisted of 247\|2 of A\|C, 240\|1 of G\|C, and 246\|2 of C\|T, respectively (Table [7](#T7){ref-type="table"}). Although the major read sequences indicated the genotypes of the non-cancerous tissues, the minor reads indicated missense mutations. The potential heteroallelic genotypes were identical to the mutated genotypes of the CC1-25, CC1-12, and CC1-8 iPSC lines. Meanwhile, the genotypes of all ten of the iPSC lines were different from the mutated genotypes in *ERBB2* and *MKNK2* of the cancer tissues and were identical to those of the non-cancerous tissues and human reference genome hg19 (Table [8](#T8){ref-type="table"}). Thus, all analyzed iPSC lines were preferentially generated from starting cells without mutations in *ERBB2* and *MKNK2*, except for those generated from mature cancer cells. Furthermore, the iPSC lines CC1-7 and CC1-17 did not have any confirmed mutated genotypes despite originating from the cancer tissue.

###### 

Chromosome number, genome position, reference vs single-nucleotide variant, novelty vs dbSNP135, gene symbol, and mutation types of single-nucleotide variants

  **SNV No**.   **Chromo-some No**.   **Genome position**   **Ref.\|SNV**   **Novel/known**   **Gene symbol**   **Mutation types**
  ------------- --------------------- --------------------- --------------- ----------------- ----------------- --------------------
  1             chr2                  37336419              C\|T            Novel             *EIF2AK2*         Missense
  2             chr2                  179408086             A\|G            Novel             *TTN*             Missense
  3             chr3                  41705179              A\|C            Novel             *ULK4*            Missense
  4             chr5                  112769527             C\|T            Novel             *TSSK1B*          Missense
  5             chr5                  180048626             C\|T            Novel             *FLT4*            Missense
  6             chr6                  31947203              T\|C            Novel             *STK19*           Missense
  7             chr7                  23808650              G\|T            Novel             *STK31*           Missense
  8             chr7                  98490141              G\|C            Novel             *TRRAP*           Missense
  9             chr12                 1009680               C\|T            Novel             *WNK1*            Missense
  10            chr16                 23690401              C\|T            Novel             *PLK1*            Missense
  11            chr17                 8789811               G\|A            Novel             *PIK3R5*          Nonsense
  12            chr17                 37881392              A\|G            Novel             *ERBB2*           Missense
  13            chr19                 2046399               G\|A            Novel             *MKNK2*           Missense

Ref.: The allele of the human reference genome hg19; SNV: Single-nucleotide variant.

###### 

Allelic depth of single-nucleotide variants among the matched adjacent non-cancerous tissue, the starting cancer tissue, and the cancer tissue-derived induced pluripotent stem cell lines

       **Allelic depth of SNVs**                                                                                                          
  ---- --------------------------- --------- -------- ---------- -------- ---------- ---------- ---------- ---------- -------- ---------- ----------
  1    250\|0                      246\|0    232\|0   250\|0     250\|0   250\|0     250\|0     248\|0     250\|0     250\|0   129\|121   250\|0
  2    249\|0                      240\|0    240\|0   248\|0     248\|1   250\|0     129\|121   248\|0     242\|0     250\|0   250\|0     244\|0
  3    246\|0                      247\|2    249\|0   238\|1     246\|0   248\|0     233\|0     241\|0     238\|1     241\|0   245\|0     132\|106
  4    250\|0                      239\|0    243\|0   248\|0     245\|0   120\|129   250\|0     236\|0     250\|0     250\|0   250\|0     249\|0
  5    216\|0                      150\|0    75\|79   189\|0     184\|0   180\|0     200\|1     131\|0     176\|0     221\|0   207\|0     179\|0
  6    249\|0                      238\|0    250\|0   132\|114   250\|0   250\|0     242\|0     248\|0     248\|0     250\|0   250\|0     249\|0
  7    250\|0                      248\|0    250\|0   250\|0     245\|0   246\|0     245\|0     135\|111   249\|0     250\|0   250\|0     246\|1
  8    233\|0                      240\|1    243\|0   250\|0     245\|0   242\|0     247\|0     248\|0     132\|113   240\|1   247\|0     241\|0
  9    249\|0                      246\|2    250\|0   250\|0     249\|0   220\|30    244\|0     249\|0     250\|0     249\|1   250\|0     249\|0
  10   247\|0                      177\|0    188\|0   119\|121   198\|0   244\|0     241\|0     176\|0     221\|0     224\|0   249\|0     174\|0
  11   246\|1                      172\|0    181\|0   208\|0     209\|0   198\|0     189\|0     175\|0     244\|0     182\|0   233\|0     95\|87
  12   249\|1                      195\|54   241\|0   249\|0     249\|0   249\|1     249\|0     250\|0     249\|0     250\|0   249\|1     250\|0
  13   137\|0                      91\|10    79\|0    131\|0     102\|0   103\|0     103\|0     83\|0      106\|0     111\|0   142\|0     90\|0

NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the induced pluripotent stem cell lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line; SNV: Single-nucleotide variant.

###### 

Genotypes of single-nucleotide variants among the matched adjacent non-cancerous tissue, the starting cancer tissue, and the cancer tissue-derived induced pluripotent stem cell lines

       **Genotypes of SNVs**                                                               
  ---- ----------------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  1    C/C                     C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/T   C/C
  2    A/A                     A/A   A/A   A/A   A/A   A/A   A/G   A/A   A/A   A/A   A/A   A/A
  3    A/A                     A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/C
  4    C/C                     C/C   C/C   C/C   C/C   C/T   C/C   C/C   C/C   C/C   C/C   C/C
  5    C/C                     C/C   C/T   C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/C
  6    T/T                     T/T   T/T   T/C   T/T   T/T   T/T   T/T   T/T   T/T   T/T   T/T
  7    G/G                     G/G   G/G   G/G   G/G   G/G   G/G   G/T   G/G   G/G   G/G   G/G
  8    G/G                     G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/C   G/G   G/G   G/G
  9    C/C                     C/C   C/C   C/C   C/C   C/T   C/C   C/C   C/C   C/C   C/C   C/C
  10   C/C                     C/C   C/C   C/T   C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/C
  11   G/G                     G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/A
  12   A/A                     A/G   A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/A   A/A
  13   G/G                     G/A   G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/G   G/G

NCC1: The matched adjacent non-cancerous tissue; CC1: The starting cancer tissue of the induced pluripotent stem cell lines; CC1-1 to CC1-25: Each induced pluripotent stem cell line; SNV: Single-nucleotide variant.

DISCUSSION
==========

The ten iPSC lines were clonally generated from a heterogeneous mixture of primary cells derived from the colon cancer tissue of a single patient. The genomes of the ten iPSC lines were analyzed using next-generation sequencing. The genomes of the starting cancer tissue and matched adjacent non-cancerous tissue from the same donor were also analyzed. The target region for analysis was the human kinome and cancer-related genes that are typically mutated in human tumors. A total of 378 non-synonymous SNVs identified from samples of the ten iPSC lines and the cancerous and non-cancerous tissues were identified by comparing the sequence reads to the human reference genome hg19. Most of the non-synonymous SNVs showed the genotype of the non-cancerous tissue, suggesting their germline origin. The SNVs of the ten iPSC lines were compared with those of the cancerous and non-cancerous tissues. Forty of the SNVs were distinct genotypes among all twelve samples. Thirteen of the forty SNVs were confirmed using allelic depth, genotype quality, and the Integrative Genomics Viewer.

In eight of the ten iPSC lines, one or two novel, non-synonymous SNVs (heteroallelic missense or nonsense mutation) in *EIF2AK2, TTN, ULK4, TSSK1B, FLT4, STK19, STK31, TRRAP, WNK1, PLK1* or *PIK3R5* were identified as genotypes different from those of the non-cancerous tissue. Unexpectedly, all the SNVs were not identical to the genotypes found in the cancer tissues. Because of minor read sequences, the potential genotype of *ULK4, TRRAP* or *WNK1* in the cancer tissues was implied. The sequences indicated a missense mutation in *ULK4, TRRAP* or *WNK1* identical to that found in the iPSC lines CC1-25, CC1-12, and CC1-8. Accordingly, there is a possibility that each iPSC line was generated from a starting cell from a minor cell population with a mutation in *ULK4, TRRAP*, or *WNK1* that was present within the cancer tissue. The minor read sequences could be confirmed by ultra-deep sequencing to support the potential heteroallelic genotypes. Interestingly, two iPSC lines CC1-7 and CC1-17 did not have any confirmed mutated genotypes despite originating from the cancer tissues. Therefore, the two iPSC lines might be generated from non-cancerous cells such as pre-cancer (stem) cells and cancer-associated fibroblasts\[[@B15],[@B16]\].

The SNVs of the ten iPSC lines could be *de novo* or pre-existing mutations that originated from minor cell populations, such as multifocal cancer (stem) cells and pre-metastatic cancer cells, present within the heterogeneous cancer tissue. Primary cancer tissues include multifocal pre-, mature and pre-metastatic cancer cells, so it makes sense that their genomes would be heterogeneous. The genotypes of pre-cancer (stem) cells would not be identical to those of germline or mature cancer cells, as colon cancer develops from an adenoma to carcinoma through the accumulation of a number of genetic mutations and epigenetic aberration\[[@B17]\]. It is likely that the genotypes of pre-metastatic cancer cells in multiple clonal evolutions would be different from those of non-metastatic cancer cells. Meanwhile, genotypes of major mature cancer cells would be identical to those of cancer tissues; therefore, it was expected that genotypes of cancer tissue-derived iPSC lines would be identical to those of their starting cancer tissues. It was reported that *ERBB2* mutations were persistent in 3.6% of patients with colorectal cancer\[[@B18]\]. Indeed, a mutated genotype in *ERBB2* of the colon cancer tissues was also identified in this study.

Nevertheless, the genotypes of the ten iPSC lines were different from the mutated *ERBB2* and *MKNK*2 genotypes in the cancer tissues and were identical to those of the non-cancerous tissues and the human reference genome hg19. This result suggests that the starting cells for the iPSC lines did not carry the mutations in *ERBB2* and *MKNK*2 present in the cancer tissues. It is conceivable that the non-mutated genotypes of each iPSC line were identical to those of non-cancerous cells such as pre-cancer (stem) cells, stroma cells and immune cells that existed within the tissue. Each iPSC line was clonally established by selecting an independent single colony expanded from a putative single starting cell originating from heterogeneous cancer tissue. The genome sequence of each iPSC line was derived from its starting single cell. As a result, each iPSC line conserved the non-mutated *ERBB2* and *MKNK*2 genotypes that originated from their respective starting single cells. Interestingly, all ten iPSC lines were not generated from cell populations containing either a mutated *ERBB2* and/or a mutated *MKNK2*. Thus, the genotypes of each iPSC line provide information on the genomic origin of the starting single cell derived from the heterogeneous cancer tissue.

Although the cause of the preference for the genomic origin of their starting cells was not clarified in this study, it seems that chemicals\[[@B19]\], gene sets\[[@B1],[@B4]\], gene transfer\[[@B20],[@B21]\], or inventive pre-culture\[[@B22],[@B23]\], in which the starting cells might be preferentially specified, can affect iPSC generation. Accordingly, materials and methods can be optimized to generate normal or aberrant iPSC lines for the purposes of regenerative medicine or cancer research/therapy. Cancer tissues comprise (pre-) cancer (stem) cells, pre-metastatic cancer cells, stromal cells (such as mesenchymal stem cells, cancer-associated fibroblasts\[[@B15],[@B16],[@B24]\] and tumor endothelial cells) and immune cells (such as tumor-associated macrophages\[[@B25]\], dendritic cells\[[@B26]\] and tumor-infiltrating T cells\[[@B23]\]). Therefore, such a cell-derived iPSC line might be useful for immune-cell therapy\[[@B27]\] with cellular vaccines\[[@B28]\], dendritic cells\[[@B29]-[@B32]\] or tumor antigen-specific cytotoxic T cells\[[@B23]\], in addition to the development of models of carcinogenesis\[[@B33]-[@B35]\] and drug discovery tools\[[@B36],[@B37]\]. For the purposes of regenerative medicine, human iPSCs are ideally generated from normal neonatal tissues\[[@B3],[@B38]-[@B40]\] that are typically inexperienced of postnatal aberrant mutations or epigenetic changes. By contrast, aging and sun-exposed skin carries thousands of evolving clonal cells carrying cancer-causing mutations\[[@B41],[@B42]\]. Indeed, genetic mutations accumulate gradually over a lifetime, even in human somatic stem cells\[[@B43]\]. For this reason, cell sources for iPSC generation should be selected based on the given field of research. Furthermore, iPSC lines with few or no mutations need to be established by the modification of existing methodology\[[@B39],[@B44],[@B45]\], as cell lines with *de novo* mutations not originating from the starting cells are not desired\[[@B46]-[@B50]\].

Nevertheless, cancer tissue-derived iPSCs might give rise to such *de novo* mutations, as their starting cells might have already suffered from an aberration (epigenetics or gene expression) associated with *de novo* mutations or cancer. Indeed, colon cancer tissue-derived iPSC lines exhibited unique gene expression profiles, with particular upregulation of *FAM19A5* and *SLC39A7*\[[@B11]\], in comparison with those of the typical iPSC line 201B7\[[@B1]\]. *FAM19A5* and *SLC39A7* were found to be expressed at lower levels in many human iPSC and ESC lines based on a free online expression atlas (Amazonia!, <http://amazonia.transcriptome.eu/search.php>)\[[@B51]\]. *FAM19A5* was reported as a novel cholangiocarcinoma biomarker\[[@B52]\], while *SLC39A7* is an intracellular zinc transporter and a hub for tyrosine kinase activation related to diseases such as cancer\[[@B53]\]. The analysis of iPSC genomes might expose rare single cells, such as an authentic cancer stem cells present within cancer tissues. Thus, next-generation sequencing of heterogeneous cancer tissue-derived iPSC lines might reveal potential aberrations or changes originating from the cancer tissue.

In conclusion, the genotypes of iPSC lines can be used to trace the genotype of the original single cells derived from heterogeneous cancer tissues.
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COMMENTS
========

Background
----------

Starting cells for induced pluripotent stem cell (iPSC) generation should be appropriately adopted to generate normal or aberrant iPSC lines for use in regenerative medicine or cancer research/therapy. Human iPSC lines for regenerative medicine would be ideally generated from normal neonatal tissues, as they are typically free of postnatal aberrant mutations and epigenetic changes. For cancer research/therapy, it is of great interest to generate iPSCs that originate from heterogeneous cancer tissues.

Research frontiers
------------------

Microarray experiments have profiled the gene expression of human iPSC lines clonally generated from a heterogeneous mixture of primary cells derived from gastric tissue or colon cancer tissue. The gene expression profiles of such iPSC lines demonstrate differences derived from their distinct starting tissues and similarity and heterogeneity derived from their common starting heterogeneous tissue.

Innovations and breakthroughs
-----------------------------

This is the first study to analyze human iPSC lines clonally generated from a heterogeneous mixture of primary cells derived from cancer tissues using next-generation sequencing. Eight of the ten iPSC lines had single-nucleotide variants with *de novo* or pre-existing mutations originating from a minor population within the cancer tissues. Meanwhile, all other genotypes of the iPSC lines were not mutated as in the original cancer tissues. Two of the ten iPSC lines did not possess any confirmed mutated genotypes despite having been derived from cancer tissue. These results suggest that the majority of iPSC lines originated from starting cells other than major cancer cells. Thus, the genotypes of iPSC lines can be used to trace the genotypes of the starting single cells.

Applications
------------

It is conceivable that cancer tissues are made up of not only pre-cancer (stem) cells and pre-metastatic cancer cells but also stroma cells (such as mesenchymal stem cells, cancer-associated fibroblasts and tumor endothelial cells) and immune cells (such as tumor-associated macrophages, dendritic cells and tumor-infiltrating T cells). These other cell types might serve as targets for drug discovery and immune-cell therapy against cancer. Therefore, such a cell-derived iPSC line might be useful for immune-cell therapies such as cancer vaccines, dendritic cells and tumor antigen-specific cytotoxic T cells, in addition to the development of models of carcinogenesis and drug discovery tools.

Terminology
-----------

Most single-nucleotide variants are heteroallelic genotypes that are validated with allelic depth and genotype quality and manually curated using the Integrative Genomics Viewer. Deeper allelic depth of next-generation sequencing further resolves genotype variations among the starting single cells present within heterogeneous cancer tissues. In this way, the genotypes of the iPSC lines may be used to trace the genomic identity of their starting single cells derived from a heterogeneous cancer tissue.

Peer-review
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